Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

PROCTER & GAMBLE SHIPPING NYQUIL HOT THERAPY TO TRADE IN MID- JULY, the firm said. NyQuil Hot Therapy, which is being touted as the only cough/cold product with "real honey lemon taste" and "soothing Vicks vapor," is expected to reach retail shelves by the beginning of August. P&G expects to use a selling line slightly modified from its regular NyQuil tag: "The nighttime, sniffling, sneezing, coughing, aching, stuffy head, fever so you can rest hot liquid medicine." New York-based DMB&B, which promotes the existing NyQuil line, will pick up the extension, the company said. NyQuil Hot Therapy will be available in boxes of six and 10 packets of the honey lemon flavor. The product is indicated to relieve coughs due to minor sore throat, bronchial irritations, runny nose and sneezing due to the common cold, the same indications as P&G's existing NyQuil line. NyQuil Hot Therapy also contains the same active ingredients as the current NyQuil product offerings: acetaminophen (1,000 mg), pseudoephedrine (60 mg), dextromethorphan (30 mg) and doxylamine succinate (12.5 g). NyQuil Hot Therapy will follow in the footsteps of Sandoz' TheraFlu, which virtually created the hot liquid cough/cold remedy category when it was launched in 1989. Since then, TheraFlu has been able to carve out a significant share of the OTC cough/cold market. The Sandoz product generated $ 33 mil. in sales in 1991.

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts